450 related articles for article (PubMed ID: 17899215)
1. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
[TBL] [Abstract][Full Text] [Related]
2. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
[TBL] [Abstract][Full Text] [Related]
3. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
Uys A; Rapoport BL; Anderson R
Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
[TBL] [Abstract][Full Text] [Related]
4. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies.
Cherif H; Johansson E; Björkholm M; Kalin M
Haematologica; 2006 Feb; 91(2):215-22. PubMed ID: 16461306
[TBL] [Abstract][Full Text] [Related]
5. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge.
Sebban C; Dussart S; Fuhrmann C; Ghesquieres H; Rodrigues I; Geoffrois L; Devaux Y; Lancry L; Chvetzoff G; Bachelot T; Chelghoum M; Biron P
Support Care Cancer; 2008 Sep; 16(9):1017-23. PubMed ID: 18197434
[TBL] [Abstract][Full Text] [Related]
6. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
Baskaran ND; Gan GG; Adeeba K
Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
[TBL] [Abstract][Full Text] [Related]
7. Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia.
Girmenia C; Russo E; Carmosino I; Breccia M; Dragoni F; Latagliata R; Mecarocci S; Morano SG; Stefanizzi C; Alimena G
Ann Hematol; 2007 Apr; 86(4):263-70. PubMed ID: 17225113
[TBL] [Abstract][Full Text] [Related]
8. [Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
Borget I; Antoun S; Chachaty E; Gachot B; Alibay A; Di Palma M; Merad M
Bull Cancer; 2014 Oct; 101(10):925-31. PubMed ID: 25373692
[TBL] [Abstract][Full Text] [Related]
9. Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: is risk stratification useful?
Gunderson CC; Farrell R; Dinh BC; Thomas ED; Vesely SK; Lauer JK; Kao L; Chopra S; McMeekin DS; Moore KN
Gynecol Oncol; 2013 Sep; 130(3):411-5. PubMed ID: 23791827
[TBL] [Abstract][Full Text] [Related]
10. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.
Klastersky J; Paesmans M; Georgala A; Muanza F; Plehiers B; Dubreucq L; Lalami Y; Aoun M; Barette M
J Clin Oncol; 2006 Sep; 24(25):4129-34. PubMed ID: 16943529
[TBL] [Abstract][Full Text] [Related]
11. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia.
Paganini H; Rodriguez-Brieshcke T; Zubizarreta P; Latella A; Firpo V; Casimir L; Armada A; Fernández C; Cáceres E; Debbag R
Cancer; 2001 Apr; 91(8):1563-7. PubMed ID: 11301406
[TBL] [Abstract][Full Text] [Related]
12. Febrile neutropenia in French emergency departments: results of a prospective multicentre survey.
André S; Taboulet P; Elie C; Milpied N; Nahon M; Kierzek G; Billemont M; Perruche F; Charpentier S; Clément H; Pourriat JL; Claessens YE
Crit Care; 2010; 14(2):R68. PubMed ID: 20403164
[TBL] [Abstract][Full Text] [Related]
13. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV.
Kern WV; Marchetti O; Drgona L; Akan H; Aoun M; Akova M; de Bock R; Paesmans M; Viscoli C; Calandra T
J Clin Oncol; 2013 Mar; 31(9):1149-56. PubMed ID: 23358983
[TBL] [Abstract][Full Text] [Related]
14. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
Freifeld A; Marchigiani D; Walsh T; Chanock S; Lewis L; Hiemenz J; Hiemenz S; Hicks JE; Gill V; Steinberg SM; Pizzo PA
N Engl J Med; 1999 Jul; 341(5):305-11. PubMed ID: 10423464
[TBL] [Abstract][Full Text] [Related]
15. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10.
Uys A; Rapoport BL; Fickl H; Meyer PW; Anderson R
Eur J Cancer Care (Engl); 2007 Nov; 16(6):475-83. PubMed ID: 17944761
[TBL] [Abstract][Full Text] [Related]
16. An audit of febrile neutropenia cases from a rural cancer center in India.
Patil VM; Chakarborty S; Kumar MS; Geetha M; Dev S; Samuel S; Ahmed G; Nayanar SK; Vineetha R; Nair CK
Indian J Cancer; 2014; 51(4):487-90. PubMed ID: 26842173
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
Flowers CR; Seidenfeld J; Bow EJ; Karten C; Gleason C; Hawley DK; Kuderer NM; Langston AA; Marr KA; Rolston KV; Ramsey SD
J Clin Oncol; 2013 Feb; 31(6):794-810. PubMed ID: 23319691
[TBL] [Abstract][Full Text] [Related]
18. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia.
Ahn S; Lee YS; Lim KS; Lee JL
Support Care Cancer; 2013 Aug; 21(8):2303-8. PubMed ID: 23519568
[TBL] [Abstract][Full Text] [Related]
19. Outpatient therapy for febrile neutropenia.
Innes H; Marshall E
Curr Opin Oncol; 2007 Jul; 19(4):294-8. PubMed ID: 17545790
[TBL] [Abstract][Full Text] [Related]
20. Outpatient treatment with intravenous antimicrobial therapy and oral levofloxacin in patients with febrile neutropenia and hematological malignancies.
Bellesso M; Costa SF; Pracchia LF; Santos Dias LC; Chamone D; Dorlhiac-Llacer PE
Ann Hematol; 2011 Apr; 90(4):455-62. PubMed ID: 20852999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
